From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies

Objective Juvenile idiopathic inflammatory/immune myopathies (IIMs) constitute a highly heterogeneous group of disorders with diagnostic difficulties and prognostic uncertainties. Circulating myositis‐specific autoantibodies (MSAs) have been recognized as reliable tools for patient substratification...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2021-06, Vol.73 (6), p.1044-1052
Hauptverfasser:	Hou, Cyrielle, Durrleman, Chloé, Periou, Baptiste, Barnerias, Christine, Bodemer, Christine, Desguerre, Isabelle, Quartier, Pierre, Melki, Isabelle, Rice, Gillian I., Rodero, Mathieu P., Charuel, Jean‐Luc, Relaix, Fréderic, Bader‐Meunier, Brigitte, Authier, FrançoisJérôme, Gitiaux, Cyril
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Adolescent Autoantibodies Autoantibodies - immunology Biomarkers Biopsy Case-Control Studies Child Child, Preschool Children Correlation Cytokines - metabolism DEAD Box Protein 58 - metabolism Dermatomyositis Dermatomyositis - diagnosis Dermatomyositis - metabolism Dermatomyositis - physiopathology Diagnosis Duchenne's muscular dystrophy Dystrophy Female Humans Immunoblotting Immunohistochemistry Inflammation Interferon Interferon-Induced Helicase, IFIH1 - metabolism Life Sciences Male Melanoma Motor task performance Muscle strength Muscle, Skeletal - metabolism Muscular dystrophy Muscular Dystrophy, Duchenne - metabolism Myopathies, Structural, Congenital - metabolism Myositis Myositis - diagnosis Myositis - metabolism Myositis - physiopathology Polymerase chain reaction Prognosis Proteins Real-Time Polymerase Chain Reaction Receptors, Immunologic - metabolism Regulation Strength testing Subgroups Ubiquitin Thiolesterase - metabolism Ubiquitins - metabolism USP18 protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!